Literature DB >> 22197826

Motor nerve terminal destruction and regeneration following anti-ganglioside antibody and complement-mediated injury: an in and ex vivo imaging study in the mouse.

Angie Rupp1, Ian Morrison, Jennifer A Barrie, Susan K Halstead, Kate H Townson, Kay N Greenshields, Hugh J Willison.   

Abstract

Both the neural and glial components of the neuromuscular junction (NMJ) have been identified as potential sites for anti-ganglioside antibody (Ab) binding and complement-mediated injury in murine models for the human peripheral nerve disorder Guillain-Barré syndrome (GBS). Some patients suffering from the acute motor axonal neuropathy (AMAN) forms of GBS recover very rapidly from paralysis; it has been proposed that in these cases the injury was restricted to the distal motor axons and nerve terminals (NTs) which are able to regenerate over a very short time-frame. To test this hypothesis, the ventral neck muscles of mice (n=45) expressing cytosolic fluorescent proteins in their axons (CFP) and Schwann cells (GFP) were subjected to a single topical application of anti-ganglioside Ab followed by a source of complement. Group A (n=15) received Ab that selectively bound to the NTs, group B (n=15) received Abs that bound both to the NTs and the perisynaptic Schwann cells (pSCs) and group C (control animals; n=15) only received complement. Evolution of the injury was documented by in vivo imaging, and following euthanasia the muscles were reimaged ex vivo both quantitatively and qualitatively, either immediately, or after 1, 2, 3 or 5 days of regeneration (each n=3 per group). Within 15 minutes of complement application, a rapid loss of CFP overlying the NMJ could be seen; in group A, the GFP signal remained unchanged, whereas in group B the GFP signal was also lost. In group C no changes to either CFP or GFP were observed. At 24 h, 6% of the superficial NMJs in group A and 12% of the NMJs in group B exhibited CFP. In both groups, CFP returned within the next five days (group A: 93.5%, group B: 94%; p=0.739), with the recovery of CFP being preceded by a return of GFP-positive cells overlying the NMJ in group B. Auxiliary investigations revealed that the loss of CFP at the NMJ correlated with a loss of NT neurofilament immuno-reactivity and a return of CFP at the NMJ was accompanied by a return of neurofilament. In ultrastructural investigations, injured NTs were electron lucent and exhibited damaged mitochondria, a loss of filaments and a loss of synaptic vesicles. The examination of muscles after five days of regeneration revealed physiological NT-profiles. The results described above indicate that following a single anti-ganglioside Ab-mediated and complement-mediated attack, independent of whether there are healthy and mature perisynaptic Schwann cells overlying the NMJ, the murine NT is capable of recovering both its architectural and axolemmal integrity very rapidly. This data supports the notion that an equivalent mechanism may account for the rapid recovery seen in some clinical cases of AMAN.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22197826     DOI: 10.1016/j.expneurol.2011.12.010

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  9 in total

Review 1.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

2.  Anti-GM2 ganglioside antibodies are a biomarker for acute canine polyradiculoneuritis.

Authors:  Angie Rupp; Francesc Galban-Horcajo; Ezio Bianchi; Maurizio Dondi; Jacques Penderis; Joanna Cappell; Karl Burgess; Kaspar Matiasek; Rhona McGonigal; Hugh J Willison
Journal:  J Peripher Nerv Syst       Date:  2013-03       Impact factor: 3.494

3.  Quantitative proteomics reveals Piccolo as a candidate serological correlate of recovery from Guillain-Barré syndrome.

Authors:  Lourdes Mateos-Hernández; Margarita Villar; Ernesto Doncel-Pérez; Marco Trevisan-Herraz; Ángel García-Forcada; Francisco Romero Ganuza; Jesús Vázquez; José de la Fuente
Journal:  Oncotarget       Date:  2016-11-15

4.  An Agonist of the CXCR4 Receptor Strongly Promotes Regeneration of Degenerated Motor Axon Terminals.

Authors:  Samuele Negro; Giulia Zanetti; Andrea Mattarei; Alice Valentini; Aram Megighian; Giulia Tombesi; Alessandro Zugno; Valentina Dianin; Marco Pirazzini; Silvia Fillo; Florigio Lista; Michela Rigoni; Cesare Montecucco
Journal:  Cells       Date:  2019-09-30       Impact factor: 6.600

5.  Latrotoxin-Induced Neuromuscular Junction Degeneration Reveals Urocortin 2 as a Critical Contributor to Motor Axon Terminal Regeneration.

Authors:  Giorgia D'Este; Marco Stazi; Samuele Negro; Aram Megighian; Florigio Lista; Ornella Rossetto; Cesare Montecucco; Michela Rigoni; Marco Pirazzini
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

Review 6.  Models and methods to study Schwann cells.

Authors:  Samuele Negro; Marco Pirazzini; Michela Rigoni
Journal:  J Anat       Date:  2022-01-05       Impact factor: 2.921

7.  An animal model of Miller Fisher syndrome: Mitochondrial hydrogen peroxide is produced by the autoimmune attack of nerve terminals and activates Schwann cells.

Authors:  Umberto Rodella; Michele Scorzeto; Elisa Duregotti; Samuele Negro; Bryan C Dickinson; Christopher J Chang; Nobuhiro Yuki; Michela Rigoni; Cesare Montecucco
Journal:  Neurobiol Dis       Date:  2016-09-03       Impact factor: 5.996

8.  The effects of age and ganglioside composition on the rate of motor nerve terminal regeneration following antibody-mediated injury in mice.

Authors:  Angie Rupp; Madeleine E Cunningham; Denggao Yao; Koichi Furukawa; Hugh J Willison
Journal:  Synapse       Date:  2013-03-14       Impact factor: 2.562

9.  Perisynaptic Schwann cells phagocytose nerve terminal debris in a mouse model of Guillain-Barré syndrome.

Authors:  Madeleine E Cunningham; Gavin R Meehan; Sophie Robinson; Denggao Yao; Rhona McGonigal; Hugh J Willison
Journal:  J Peripher Nerv Syst       Date:  2020-04-20       Impact factor: 5.188

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.